长坡厚雪的赛道,也吸引了资本市场进场。而作为减肥市场上的竞争者诺和诺德与礼来,市值都超过3000亿美元。于是,减肥领域,两者开始刀枪相接,一场比降糖胰岛素更激烈的GLP-1减重战争正在展开。
Time:
2023-05-10 14:59
Author:
xieyijun
股市依然艰难,IPO窗口几乎没有打开,风险投资公司还在勒紧裤腰带——对该行业规模较小的卖家来说,这些因素将使他们在未来几个月的谈判桌上面临窘境。
Time:
2023-05-10 15:05
Author:
xieyijun
按现有模式,绝大多数Biotech商业化在中国无法盈利可能是个必然的结果!那么造成这种情况的底层原因是什么,到底有没有解决的办法呢?
Time:
2023-05-10 15:08
Author:
xieyijun
抗体药物国家重点实验室数据最新发布:国产“激流”反应器规模生产批蛋白表达量较进口反应器成熟工艺提高近40%
美国、俄罗斯、印度等国家的客户陆续来金仪盛世洽谈合作及验厂审计,美国客户当即签署了金额达数千万的采购订单。
Time:
2023-05-10 15:12
Author:
xieyijun
MNC、Biotech抢占的高地,iPSC数十亿美元市场有哪些机会?
诱导多能干细胞(iPSC)有多热?资本和市场的走势可见一斑。
Time:
2023-05-10 15:39
Author:
xieyijun
经历了一年蹉跎岁月的全球生物技术医药开发行业翘盼春暖花开,然而硅谷银行的突然崩溃,却给所有的新兴高技术企业带来了一场严峻的倒春寒。
Time:
2023-05-11 13:18
Author:
写意君
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence